Evaluation of safety and immunogenicity of a new octavalent inactivated vaccine containing porcine parvovirus, erysipelas, and leptospira

돼지 파보바이러스, 단독 및 렙토스피라 8가 불활화 백신의 안전성 및 면역원성 평가

  • Kim, Kiju (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University) ;
  • Choi, Jong-Young (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University) ;
  • Park, Su-Jin (Zoetis Korea) ;
  • Hahn, Tae-Wook (College of Veterinary Medicine & Institute of Veterinary Science, Kangwon National University)
  • 김기주 (강원대학교 수의과대학 및 동물의학종합연구소) ;
  • 최종영 (강원대학교 수의과대학 및 동물의학종합연구소) ;
  • 박수진 (조에티스 코리아) ;
  • 한태욱 (강원대학교 수의과대학 및 동물의학종합연구소)
  • Received : 2017.01.19
  • Accepted : 2017.07.11
  • Published : 2017.09.30


Porcine parvovirus, Erysipelothrix (E.) rhusiopathiae, and Leptospira (L.) interrogans are considered major etiologic agents of reproductive failure in pigs, causing economic loss in the swine industry. In this study, the safety and immunogenicity of a new octavalent inactivated vaccine were evaluated. The vaccine contained inactivated porcine parvovirus, E. rhusiopathiae, and six L. interrogans serovars (Bratislava, Canicola, Grippotyphosa, Hardjo, Icterohaemorrhagiae, and Pomona). Safety test results showed no notable side effects or clinical signs after vaccination in mice, guinea pigs, and sows. In addition, we assessed immunogenicity of the vaccine in 25 sows under field conditions. The vaccinated group (n = 20) had a significantly higher antibody level than the non-vaccinated group (n = 5). Moreover, the stillbirth rate decreased in piglets born from vaccinated sows, resulting in an increased fertility rate. The results of this study demonstrate that the new octavalent inactivated vaccine can be applied safely and effectively to improve reproductive performance in sows.


Supported by : 강원대학교


  1. Opriessnig T, Xiao CT, Gerber PF, Halbur PG. Identification of recently described porcine parvoviruses in archived North American samples from 1996 and association with porcine circovirus associated disease. Vet Microbiol 2014, 173, 9-16.
  2. Ren X, Tao Y, Cui J, Suo S, Cong Y, Tijssen P. Phylogeny and evolution of porcine parvovirus. Virus Res 2013, 178, 392-397.
  3. Streck AF, Bonatto SL, Homeier T, Souza CK, Gonçalves KR, Gava D, Canal CW, Truyen U. High rate of viral evolution in the capsid protein of porcine parvovirus. J Gen Virol 2011, 92, 2628-2636.
  4. Streck AF, Canal CW, Truyen U. Molecular epidemiology and evolution of porcine parvoviruses. Infect Genet Evol 2015, 36, 300-306.
  5. Zeeuw EJ, Leinecker N, Herwig V, Selbitz HJ, Truyen U. Study of the virulence and cross-neutralization capability of recent porcine parvovirus field isolates and vaccine viruses in experimentally infected pregnant gilts. J Gen Virol 2007, 88, 420-427.
  6. Miraglia F, Moreno LZ, Morais ZM, Langoni H, Shimabukuro FH, Dellagostin OA, Hartskeerl R, Vasconcellos SA, Moreno AM. Characterization of Leptospira interrogans serovar Pomona isolated from swine in Brazil. J Infect Dev Ctries 2015, 9, 1054-1061.
  7. Molitor TW, Joo HS, Collett MS. Porcine parvovirus: virus purification and structural and antigenic properties of virion polypeptides. J Virol 1983, 45, 842-854.
  8. Back YS, Lee JS, Kim YE, Kim BH. [Bacteriological study of Erysipelothrix rhusiopathiae isolated from the pigs in Youngnam area]. Korean J Vet Serv 1991, 14, 49-61. Korean.
  9. Borrathybay E, Gong FJ, Zhang L, Nazierbieke W. Role of surface protective antigen A in the pathogenesis of Erysipelothrix rhusiopathiae strain C43065. J Microbiol Biotechnol 2015, 25, 206-216.
  10. Choi H, Won H, Yoon I. [Efficacy test of swine erysipelas inactivated vaccine]. Korean J Vet Public Health 2008, 32, 135-140. Korean.
  11. Fidalgo SG, Riley TV. Detection of Erysipelothrix rhusiopathiae in clinical and environmental samples. Methods Mol Biol 2004, 268, 199-205.
  12. Friendship CR, Bilkei G. Concurrent swine erysipelas and Clostridium novyi infections associated with sow mortality in outdoor sows in Kenya. Vet J 2007, 173, 694-696.
  13. Guo C, Zhong Z, Huang Y. Production and immunogenicity of VP2 protein of porcine parvovirus expressed in Pichia pastoris. Arch Virol 2014, 159, 963-970.
  14. Hartleben CP, Leal FMA, Monte LG, Hartwig DD, Seixas FK, Vasconcellos SA, Brihuega B, Dellagostin OA. Serological analysis by enzyme-linked immunosorbent assay using recombinant antigen LipL32 for the diagnosis of swine leptospirosis. Curr Microbiol 2013, 66, 106-109.
  15. Jacobs AA, Harks F, Hoeijmakers M, Collell M, Segers RP. Safety and efficacy of a new octavalent combined Erysipelas, Parvo and Leptospira vaccine in gilts against Leptospira interrogans serovar Pomona associated disease and foetal death. Vaccine 2015, 33, 3963-3969.
  16. Levett PN. Leptospirosis. Clin Microbiol Rev 2001, 14, 296-326.
  17. Li X, Zhu L, Liu X, Sun X, Zhou Y, Lang Q, Li P, Cai Y, Qiao X, Xu Z. Differential expression of microRNAs in porcine parvovirus infected porcine cell line. Virol J 2015, 12, 128.
  18. Mayr A, Bachmann P, Siegl G, Mahnel H, Sheffy BE. Characterization of a small porcine DNA virus. Arch Gesamte Virusforsch 1968, 25, 38-51.